Mario Alberto Accardi - Jun 13, 2025 Form 3 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
President, Orexin Program
Signature
/s/ Iqbal Hussain, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Jun 13, 2025
Transactions value $
$0
Form type
3
Date filed
6/24/2025, 04:08 PM
Next filing
Jun 25, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Accardi Mario Alberto President, Orexin Program C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Iqbal Hussain, attorney-in-fact 2025-06-23 0002074392

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CNTA Ordinary Shares 216K Jun 13, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CNTA Share Option (right to buy) Jun 13, 2025 Ordinary Shares 11.3K $9.53 Direct F1, F3
holding CNTA Share Option (right to buy) Jun 13, 2025 Ordinary Shares 16.9K $9.53 Direct F1, F4
holding CNTA Share Option (right to buy) Jun 13, 2025 Ordinary Shares 30.3K $3.85 Direct F1, F5
holding CNTA Share Option (right to buy) Jun 13, 2025 Ordinary Shares 40K $8.01 Direct F1, F6
holding CNTA Share Option (right to buy) Jun 13, 2025 Ordinary Shares 225K $16.90 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Includes 25,150 Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer.
F3 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments with the first installment vesting on March 1, 2022.
F4 Represents the vested portion of such option granted on February 1, 2022 that vests upon the achievement of applicable performance goals.
F5 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
F6 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.
F7 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2025.

Remarks:

Exhibit 24 - Power of Attorney